Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$0.54 USD
-0.02 (-2.80%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $0.54 0.00 (-0.44%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPSC 0.54 -0.02(-2.80%)
Will IPSC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates
Other News for IPSC
Century Therapeutics files $200M mixed shelf offering
Century Therapeutics (IPSC) Files for $200M Mixed Securities Offering | IPSC Stock News
Century Therapeutics files $200M mixed securities shelf
Century Therapeutics Holds 2025 Annual Stockholders Meeting
Leerink Partners Keeps Their Buy Rating on Century Therapeutics (IPSC)